[Evaluation of hepatic microsomal enzyme activity using C-l4-labeled aminopyrine breath test in patients with diabetes mellitus type 2 treated with tolbutamide].
Among 116 diabetic patients of the District Diabetic Polyclinic in Zabrze (51 type II treated with tolbutamide++, 36 type I treated with insulin, 29 type II treated with diet only) and 30 health persons functional microsomal hepatic fraction with ABT was assessed. Classical hepatic function test were done too. Among 49% patients under examination with type II diabetes treated with tolbutamide++ statistically significant decrease of value of ABT was observed as compared with other groups. Values of classical hepatic function tests in investigated patients were within normal values. Decrease in demethylation of aminopyrine shown as the abnormality in values of ABT can be considered as early symptom of hepatocyte damage caused by tolbutamide++. ABT is valuable method of appraising the liver's detoxication function in type II diabetes. Patients treated with tolbutamide++ should not receive any other drug known as inhibitor of microsomal enzymes of the liver.
Kamińska-Galwas
B
B
Katedry i Kliniki Chorób Wewnetrznych i Zawodowych Slaskiej Akademii Medycznej w Katowicach.
Sroczyński
J
J
D000328:Adult; D000368:Aged; D000632:Aminopyrine; D001944:Breath Tests / Q000379:methods; D002250:Carbon Radioisotopes; D003577:Cytochrome P-450 Enzyme System / Q000378:metabolism*; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy / Q000201:enzymology / Q000378:metabolism*; D005260:Female; D006801:Humans; D008658:Inactivation, Metabolic / Q000502:physiology; D008111:Liver Function Tests / Q000379:methods; D008297:Male; D008862:Microsomes, Liver / Q000201:enzymology / Q000378:metabolism*; D008875:Middle Aged; D014044:Tolbutamide / Q000493:pharmacokinetics / Q000627:therapeutic use*
D002250:Carbon Radioisotopes; D000632:Aminopyrine; D003577:Cytochrome P-450 Enzyme System; D014044:Tolbutamide
Ocena aktywności enzymów mikrosomalnych watroby za pomoca testu oddechowego z zastosowaniem 14C-aminopiryny u chorych na cukrzyce typu II leczonych tolbutamidem.